Myos Corp (MYOS) 12.4000 $MYOS
MYOS Corporation Teams Up With NFL Alumni in Optimal Bowl and Wellness Challenge
Marketwire - Thu Apr 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a participating sponsor of The NFL Alumni's Optimal Bowl and Wellness Challenge featuring former NFL players in a not-for-profit wellness project. The 60-day challenge will feature teams of former NFL players and military veterans working together with world class medical specialists in a variety of activities designed to improve their individual health. In addition to sponsoring this wellness challenge, MYOS is partnering with the NFL Alumni by providing challenge participants with the opportunity to utilize the Company's first commercial product MYO-X(R), powered by MYO-T12(R).
MYOS Corporation Studies Muscle and Strength Building Activity of Fortetropin in Resistance Trained Male Subjects
Marketwire - Wed Apr 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today the initiation of a clinical study of Fortetropin(TM) (also known as MYO-T12(R)) conducted in resistance trained male subjects. The study, being led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa, a world leading muscle physiology laboratory, will study the effects of Fortetropin on increasing skeletal muscle mass and strength in male subjects.
MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
Marketwire - Tue Apr 01, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS)
MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
Marketwire - Thu Mar 27, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", announced today that it will participate in a working group on March 28, 2014 including physicians, researchers, patient groups and the U.S. Food and Drug Administration (FDA) to develop measures of clinical benefit for therapeutic products developed or used to treat sarcopenia. The group, the Aging in Motion (AIM) Coalition, was formed to promote understanding about the importance of improving research efforts and developing innovative treatments in the area of sarcopenia and age-related functional decline. At present, the FDA does not have a policy on sarcopenia and currently there are no drugs approved for this disease indication.
MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
Marketwire - Mon Mar 17, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", announced today that the Company will participate in the New Jersey MDA Muscle Walk fundraising event on March 23, 2014 at the Prudential Center in Newark, NJ.
MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
Marketwire - Wed Mar 12, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014.
MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
MYOS Corporation Appoints Christopher Pechock to Its Board of Directors
Marketwire - Mon Feb 24, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", announced today that it has appointed Christopher Pechock to its Board of Directors.
MYOS Board of Directors Issues Letter to Shareholders
Marketwire - Mon Feb 10, 6:35AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", issued the following letter to its shareholders:
MYOS Corporation Announces 1-for-50 Reverse Stock Split Following Five Consecutive Quarters of Market Expansion and Revenue Growth
Marketwire - Mon Feb 10, 6:30AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company", announced that it is effecting a 1-for-50 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on February 10, 2014. As of that date, each 50 shares of issued and outstanding common stock will be converted into 1 share of common stock. Beginning on February 10, 2014, the Company's common stock will trade on the OTC Bulletin Board under the symbol "MYOSD," with the fifth character "D" added to the end of the trading symbol, for a period of 20 trading days to indicate that the reverse stock split has occurred. The Company's common stock will revert to trading under its original symbol "MYOS" after the 20 trading day period.
MYOS Corporation raises USD4.735m from private placement
M2 - Wed Jan 29, 5:49AM CST
US-based biotherapeutics company MYOS Corporation (Other OTC:MYOS) stated on Tuesday that it has completed its USD4.735m private equity financing with various accredited investors.
MYOS Corporation Closes $4.735 Million Private Placement
Marketwire - Tue Jan 28, 7:26AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance (the "Company", today announced that it has closed a $4.735 million private equity financing with various accredited investors.
MYOS Corporation Announces Third Quarter Results;
Marketwire - Thu Nov 07, 7:25AM CST
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company", today announced highlights of its financial results for the third quarter ended September 30, 2013, and the launch of its study (first announced in August) evaluating the Company's lead product in combination with testosterone.
MYOS to Study Synergistic Effects of Myostatin Inhibition on Testosterone-Mediated Muscle Growth; Brigham and Women's Hospital, a Teaching Affiliate of Harvard Medical School, to Conduct the Study
Marketwire - Thu Aug 15, 7:00AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance, today announced that it will collaborate with Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, to conduct a pre-clinical study of the effects of myostatin inhibition by orally administered MYO-T12(R) on muscle tissue and body composition in conjunction with testosterone treatment.
UPDATE: MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
Marketwire - Tue Aug 13, 1:17PM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company", today announced its financial results for the second quarter ended June 30, 2013 and its recent key operational highlights representing expanded research and manufacturing accomplishments.
MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
Marketwire - Tue Aug 13, 7:02AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company", today announced its financial results for the second quarter ended June 30, 2013 and its recent key operational highlights representing expanded research and manufacturing accomplishments.
MYOS Corporation executes exclusive supply contract with Deutsches Institut fur Lebensmitteltechnik eV
M2 - Fri Jul 12, 7:11AM CDT
Human muscle health company MYOS Corporation (OTCBB:MYOS) said on Thursday that it has entered into an exclusive supply contract with Deutsches Institut fur Lebensmitteltechnik eV (DIL), the German Institute for Food Technologies.
MYOS Signs Exclusive Supply Contract, Plans New Product R&D, With DIL
Marketwire - Thu Jul 11, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today announced that it has signed an exclusive two-year supply contract with the prestigious Deutsches Institut fur Lebensmitteltechnik e.V. ("DIL" -- the German Institute for Food Technologies.
MYOS to Initiate a New Clinical Study on MYO-T12; Company Plans to Introduce Muscle Health Products for Women
Marketwire - Wed Jun 19, 7:01AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today announced that it has completed the protocol design for a new clinical study on the effects of MYO-T12 in females. MYO-T12 is the Company's flagship product and the first clinically demonstrated natural myostatin inhibitor.
MYOS Corporation Teams Up With NFL Alumni in Optimal Bowl and Wellness Challenge
Marketwire - Thu Apr 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a participating sponsor of The NFL Alumni's Optimal Bowl and Wellness Challenge featuring former NFL players in a not-for-profit wellness project. The 60-day challenge will feature teams of former NFL players and military veterans working together with world class medical specialists in a variety of activities designed to improve their individual health. In addition to sponsoring this wellness challenge, MYOS is partnering with the NFL Alumni by providing challenge participants with the opportunity to utilize the Company's first commercial product MYO-X(R), powered by MYO-T12(R). MYOS Corporation Studies Muscle and Strength Building Activity of Fortetropin in Resistance Trained Male Subjects
Marketwire - Wed Apr 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today the initiation of a clinical study of Fortetropin(TM) (also known as MYO-T12(R)) conducted in resistance trained male subjects. The study, being led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa, a world leading muscle physiology laboratory, will study the effects of Fortetropin on increasing skeletal muscle mass and strength in male subjects. MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
Marketwire - Tue Apr 01, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS)
MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
Marketwire - Thu Mar 27, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that it will participate in a working group on March 28, 2014 including physicians, researchers, patient groups and the U.S. Food and Drug Administration (FDA) to develop measures of clinical benefit for therapeutic products developed or used to treat sarcopenia. The group, the Aging in Motion (AIM) Coalition, was formed to promote understanding about the importance of improving research efforts and developing innovative treatments in the area of sarcopenia and age-related functional decline. At present, the FDA does not have a policy on sarcopenia and currently there are no drugs approved for this disease indication. MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
Marketwire - Mon Mar 17, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that the Company will participate in the New Jersey MDA Muscle Walk fundraising event on March 23, 2014 at the Prudential Center in Newark, NJ. MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
Marketwire - Wed Mar 12, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014. MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
MYOS Corporation Appoints Christopher Pechock to Its Board of Directors
Marketwire - Mon Feb 24, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that it has appointed Christopher Pechock to its Board of Directors. MYOS Board of Directors Issues Letter to Shareholders
Marketwire - Mon Feb 10, 6:35AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, issued the following letter to its shareholders: MYOS Corporation Announces 1-for-50 Reverse Stock Split Following Five Consecutive Quarters of Market Expansion and Revenue Growth
Marketwire - Mon Feb 10, 6:30AM CST
MYOS Corporation (OTCBB: MYOSD), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced that it is effecting a 1-for-50 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on February 10, 2014. As of that date, each 50 shares of issued and outstanding common stock will be converted into 1 share of common stock. Beginning on February 10, 2014, the Company's common stock will trade on the OTC Bulletin Board under the symbol "MYOSD," with the fifth character "D" added to the end of the trading symbol, for a period of 20 trading days to indicate that the reverse stock split has occurred. The Company's common stock will revert to trading under its original symbol "MYOS" after the 20 trading day period. MYOS Corporation raises USD4.735m from private placement
M2 - Wed Jan 29, 5:49AM CST
US-based biotherapeutics company MYOS Corporation (Other OTC:MYOS) stated on Tuesday that it has completed its USD4.735m private equity financing with various accredited investors.
MYOS Corporation Closes $4.735 Million Private Placement
Marketwire - Tue Jan 28, 7:26AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance (the "Company"
, today announced that it has closed a $4.735 million private equity financing with various accredited investors. MYOS Corporation Announces Third Quarter Results;
Marketwire - Thu Nov 07, 7:25AM CST
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company"
, today announced highlights of its financial results for the third quarter ended September 30, 2013, and the launch of its study (first announced in August) evaluating the Company's lead product in combination with testosterone. MYOS to Study Synergistic Effects of Myostatin Inhibition on Testosterone-Mediated Muscle Growth; Brigham and Women's Hospital, a Teaching Affiliate of Harvard Medical School, to Conduct the Study
Marketwire - Thu Aug 15, 7:00AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance, today announced that it will collaborate with Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, to conduct a pre-clinical study of the effects of myostatin inhibition by orally administered MYO-T12(R) on muscle tissue and body composition in conjunction with testosterone treatment.
UPDATE: MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
Marketwire - Tue Aug 13, 1:17PM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company"
, today announced its financial results for the second quarter ended June 30, 2013 and its recent key operational highlights representing expanded research and manufacturing accomplishments. MYOS Reports Second Quarter 2013 Financial Results and Recent Key Operational Highlights
Marketwire - Tue Aug 13, 7:02AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic and dietary products that improve human muscle health and performance ("MYOS" or the "Company"
, today announced its financial results for the second quarter ended June 30, 2013 and its recent key operational highlights representing expanded research and manufacturing accomplishments. MYOS Corporation executes exclusive supply contract with Deutsches Institut fur Lebensmitteltechnik eV
M2 - Fri Jul 12, 7:11AM CDT
Human muscle health company MYOS Corporation (OTCBB:MYOS) said on Thursday that it has entered into an exclusive supply contract with Deutsches Institut fur Lebensmitteltechnik eV (DIL), the German Institute for Food Technologies.
MYOS Signs Exclusive Supply Contract, Plans New Product R&D, With DIL
Marketwire - Thu Jul 11, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today announced that it has signed an exclusive two-year supply contract with the prestigious Deutsches Institut fur Lebensmitteltechnik e.V. ("DIL"
-- the German Institute for Food Technologies. MYOS to Initiate a New Clinical Study on MYO-T12; Company Plans to Introduce Muscle Health Products for Women
Marketwire - Wed Jun 19, 7:01AM CDT
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today announced that it has completed the protocol design for a new clinical study on the effects of MYO-T12 in females. MYO-T12 is the Company's flagship product and the first clinically demonstrated natural myostatin inhibitor.
